-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Cytokinetics to Participate in May Investor Conferences
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Cytokinetics (CYTK) PT Raised to $82 at RBC Capital Following Bayer Partnership
-
Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
-
Pre-Open Movers 02/06: (GALE) (HAS) (COG) Higher; (TIF) (IP) (BLUE) Lower (more...)
-
Pre-Open Stock Movers 06/02: (NPSP) (PL) (BRCM) Higher; (PBYI) (MTZ) (CYTK) Lower (more...)
-
Notable Analyst Rating Changes 04/25: (CELG) (SYNA) (WFC) Upgraded; (KLAC) (LLTC) (CYTK) Downgraded
-
Notable Analyst Rating Changes 03/05: (P) (TRMB) (DST) Upgraded; (DDS) (SPLS) (PEI) Downgraded
-
Pre-Open Stock Movers 2/7: (IMN) (LQDT) (EXPE) Higher; (FWM) (ELON) (LNKD) Lower (more...)
-
Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded

